Clinical trial
Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis
NCT03945487 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of Human Unbilical Cord Derived-mesenchymal Stem Cells Treatment for Patients With Decompensated Liver Cirrhosis
- Lead sponsor
- Beijing 302 Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 20, 2019
- Completion date
- December 30, 2023
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
decompensated liver cirrhosis